| 0.03 -0.004 (-10.98%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.22 | 1-year : | 0.35 |
| Resists | First : | 0.19 | Second : | 0.3 |
| Pivot price | 0.14  |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.15 |
| MA(100) : | 0.32 |
MA(250) : | 0.65 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 30.2 |
| RSI | RSI(14): 25.8 |
|||
| 52-week | High : | 1.41 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ITRM ] has closed below the lower bollinger band by 6.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ITRM ] is to continue within current trading range. Bollinger Bands are 33.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.07 - 0.07 | 0.07 - 0.07 |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Wed, 01 Apr 2026
Iterum Therapeutics plc (NASDAQ:ITRM): Are Analysts Optimistic? - Yahoo Finance
Tue, 31 Mar 2026
Iterum Therapeutics Received Notice of Delisting - TradingView
Tue, 31 Mar 2026
Iterum Therapeutics to be delisted from Nasdaq as winding up process advances - Investing.com
Mon, 30 Mar 2026
What's Going On With Iterum Therapeutics Stock Monday? - Benzinga
Fri, 27 Mar 2026
Iterum Therapeutics plc Announces Petition for Winding Up and Appointment of Joint Provisional Liquidators - Quiver Quantitative
Fri, 27 Mar 2026
Iterum Therapeutics (NASDAQ: ITRM) seeks court-backed wind up - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.237e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 1,750 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.932e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 982.3 % |
| Return on Equity (ttm) | -53.3 % |
| Qtrly Rev. Growth | 390000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 38538.2 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.61 |
| Dividend | 0 |
| Forward Dividend | 3.07e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|